LANSOPRAZOLE (lan'so-pra-zole) Prevacid, Prevacid IV Classifications: antisecretory; proton pump inhibitor; Therapeutic: antiulcer; antisecretory; proton pump inhibitor Prototype: Omeprazole Pregnancy Category: B |
15 mg, 30 mg sustained release capsules; 15 mg, 30 mg orally disintegrating tablets; 15 mg, 30 mg packets for suspension; 30 mg powder for injection
Belongs to a class of antisecretory compounds that are gastric acid pump inhibitors. Specifically, it suppresses gastric acid secretion by inhibiting the H+, K+-ATPase enzyme [the acid (proton H+) pump] in the parietal cells.
Suppresses gastric acid formation in the stomach.
Short-term treatment of duodenal ulcer (up to 4 wk) and erosive esophagitis (up to 8 wk), pathologic hypersecretory disorders, gastric ulcers; in combination with clarithromycin and amoxicillin for Helicobacter pylori. Gastroesophageal reflux disease (GERD).
Hypersensitivity to lansoprazole, severe hepatic impairment, proton pump inhibitors (PPIs) hypersensitivity, lactation, infants.
Hepatic disease, pregnancy (category B).
Duodenal Ulcer Adult: PO 15 mg once daily x 4 wk Erosive Esophagitis Adult: PO 30 mg once daily x 8 wk, then decrease to 15 mg once daily IV 30 mg once daily for up to 7 d GERD Adult: PO 15 mg once daily for up to 8 wk Child (111 y): PO 1.5 mg/kg/d (max: 30 mg/d) Hypersecretory Disorder Adult: PO 60 mg once daily (max: 120 mg/d in divided doses), may need to be adjusted for hepatic impairment H. pylori Adult: PO 30 mg b.i.d. x 2 wk, in combination with 2 antibiotics Hepatic Impairment Dose reduction required in severe hepatic disease. |
Intravenous PREPARE: IV Infusion: Add 5 mL of sterile water for injection to each 30 mg vial to yield 6 mg/mL. Swirl gently to mix. Further dilute in 50 mL of NS, RL, or D5W. If reconstituted with NS or LR, administer within 24 h. If reconstituted with D5W, administer within 12 h. ADMINISTER: IV Infusion: Infuse over 30 min through the in-line filter provided. Use a dedicated line or a Y-site; flush Y-site with NS before and after administration. Do NOT give IV push. Immediately stop infusion if precipitation or discoloration occurs. |
INCOMPATIBILITIES Solution/additive, Y-site: Do not administer with other drugs or diluents.
Assessment & Drug Effects
Patient & Family Education